|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
|
US7232818B2
(en)
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
ATE494298T1
(de)
|
2004-04-15 |
2011-01-15 |
Proteolix Inc |
Verbindungen zur proteasomenzymhemmung
|
|
SI2030981T1
(sl)
*
|
2004-05-10 |
2014-11-28 |
Onyx Therapeutics, Inc. |
Spojine za inhibiranje proteasomskega encima
|
|
AU2005243140A1
(en)
*
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
CN103230394B
(zh)
|
2004-12-03 |
2016-04-20 |
达纳-法伯癌症研究公司 |
治疗肿瘤性疾病的化合物及其用途
|
|
EP2261236B1
(en)
*
|
2004-12-07 |
2015-07-15 |
Onyx Therapeutics, Inc. |
Composition for proteasome inhibition
|
|
EP2623113B1
(en)
|
2005-11-09 |
2017-05-31 |
Onyx Therapeutics, Inc. |
Compound for enzyme inhibition
|
|
NZ597545A
(en)
|
2006-06-19 |
2013-07-26 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
EP2040694A2
(en)
*
|
2006-07-14 |
2009-04-01 |
VIB vzw |
Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
|
|
US7642369B2
(en)
*
|
2006-09-12 |
2010-01-05 |
University Of Kentucky Research Foundation |
Epoxyketone-based immunoproteasome inhibitors
|
|
AU2013203566B2
(en)
*
|
2007-10-04 |
2016-10-13 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
AU2016231532B2
(en)
*
|
2007-10-04 |
2018-05-10 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
CA2701778C
(en)
*
|
2007-10-04 |
2018-09-11 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
EP2088205A1
(en)
|
2008-02-11 |
2009-08-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
US7910616B2
(en)
|
2008-05-12 |
2011-03-22 |
Nereus Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
JP5675629B2
(ja)
*
|
2008-10-21 |
2015-02-25 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドエポキシケトンを用いた併用療法
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
US20110009332A1
(en)
*
|
2009-07-09 |
2011-01-13 |
Southwest Research Institute |
Therapeutic Treatment Of Wounds
|
|
GB0914883D0
(en)
|
2009-08-26 |
2009-09-30 |
Univ Belfast |
Compound
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
AU2011223795B2
(en)
|
2010-03-01 |
2015-11-05 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
CA2795559A1
(en)
|
2010-04-07 |
2011-11-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
|
WO2012135528A2
(en)
|
2011-03-29 |
2012-10-04 |
Texas Tech University System |
Galectin-3c combination therapy for human cancer
|
|
WO2013009923A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Creighton University |
Methods of promoting neuron growth
|
|
CN104039328B
(zh)
|
2011-11-11 |
2018-10-09 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
|
EP2776586B1
(en)
|
2011-11-11 |
2018-03-07 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
|
WO2013112601A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
HUE058834T2
(hu)
|
2012-02-15 |
2022-09-28 |
Cydex Pharmaceuticals Inc |
Elõállítási eljárás ciklodextrin-származékokhoz
|
|
AU2013259573B2
(en)
|
2012-05-08 |
2018-02-15 |
Onyx Therapeutics, Inc. |
Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
|
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
WO2014015027A1
(en)
|
2012-07-18 |
2014-01-23 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
WO2014029022A1
(en)
*
|
2012-08-21 |
2014-02-27 |
Abdelmalik Slassi |
Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
|
|
WO2014066274A1
(en)
|
2012-10-22 |
2014-05-01 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
SG10201913777XA
(en)
|
2013-03-13 |
2020-03-30 |
Sanofi Sa |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
|
SG11201507106PA
(en)
|
2013-03-14 |
2015-10-29 |
Onyx Therapeutics Inc |
Dipeptide and tripeptide epoxy ketone protease inhibitors
|
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
|
AU2014290012B2
(en)
|
2013-07-19 |
2020-01-16 |
Onyx Therapeutics, Inc. |
Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
|
|
CN103360348B
(zh)
*
|
2013-07-25 |
2015-06-24 |
苏州鹏旭医药科技有限公司 |
一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
|
|
CA2922210A1
(en)
*
|
2013-09-06 |
2015-03-12 |
Sandoz Ag |
Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
|
|
WO2015032621A1
(en)
*
|
2013-09-06 |
2015-03-12 |
Sandoz Ag |
Synthesis of peptide epoxy ketones
|
|
WO2015121769A1
(en)
|
2014-02-13 |
2015-08-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
|
|
CN103864889B
(zh)
*
|
2014-04-04 |
2017-01-11 |
重庆泰濠制药有限公司 |
环氧酮化合物、其制备方法及卡非佐米的制备方法
|
|
HUE063851T2
(hu)
|
2014-08-22 |
2024-02-28 |
Cydex Pharmaceuticals Inc |
Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
|
|
WO2016046843A1
(en)
|
2014-09-24 |
2016-03-31 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
|
|
US20160115198A1
(en)
|
2014-10-27 |
2016-04-28 |
Apicore Us Llc |
Methods of making carfilzomib and intermediates thereof
|
|
CN104402973A
(zh)
*
|
2014-11-24 |
2015-03-11 |
重庆泰濠制药有限公司 |
一种卡非佐米无定型晶的制备方法
|
|
WO2016088031A1
(en)
|
2014-12-02 |
2016-06-09 |
Fresenius Kabi Oncology Limited |
A process for purification of carfilzomib
|
|
WO2016108204A1
(en)
|
2014-12-31 |
2016-07-07 |
Dr. Reddy's Laboratories Limited |
Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
|
|
WO2016170544A1
(en)
*
|
2015-04-22 |
2016-10-27 |
Msn Laboratories Private Limited |
Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide
|
|
ES2888800T3
(es)
|
2015-05-21 |
2022-01-07 |
Laurus Labs Ltd |
Procedimiento mejorado para la preparación de carfilzomib o sales farmacéuticamente aceptables del mismo
|
|
CN106317188A
(zh)
*
|
2015-06-18 |
2017-01-11 |
重庆医药工业研究院有限责任公司 |
一种制备卡非佐米无定型物的方法
|
|
WO2017032487A1
(en)
|
2015-08-27 |
2017-03-02 |
Technische Universität München |
Proteasome inhibitor comprising a signal-emitting moiety
|
|
WO2017098532A1
(en)
|
2015-12-11 |
2017-06-15 |
Mylan Laboratories Limited |
Crystalline and amorphous forms of carfilzomib
|
|
TWI636052B
(zh)
*
|
2015-12-31 |
2018-09-21 |
中化合成生技股份有限公司 |
無定形卡非佐米(i)的製備方法
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
TWI759301B
(zh)
*
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
|
WO2018024645A1
(en)
|
2016-08-02 |
2018-02-08 |
Synthon B.V. |
Process for making carfilzomib
|
|
UA125648C2
(uk)
|
2016-08-05 |
2022-05-11 |
Емджен Інк. |
Синтез (s)-2-аміно-4-метил-1-((r)-2-метилоксиран-2-іл)-пентан-1-ону та його фармацевтично прийнятних солей
|
|
ES2874683T3
(es)
|
2016-09-14 |
2021-11-05 |
Fresenius Kabi Oncology Ltd |
Un proceso para la purificación de un intermedio de carfilzomib
|
|
ES2978159T3
(es)
|
2016-09-16 |
2024-09-06 |
Hsf Pharmaceuticals |
Inhibidores de factores de choque térmico (HSF) y usos de los mismos
|
|
EP3330260A1
(en)
|
2016-12-01 |
2018-06-06 |
Enantia, S.L. |
Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
|
|
BR112020005079A2
(pt)
|
2017-09-14 |
2020-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
tratamento de combinação para câncer
|
|
WO2019099715A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Stable compositions of pegylated carfilzomib compounds
|
|
EP3735587B1
(en)
*
|
2017-12-08 |
2024-10-30 |
NeuroGX LLC |
Synchronized cell cycle gene expression test for alzheimer's disease and related therapeutic methods
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
AU2018357829B2
(en)
|
2017-12-30 |
2019-09-26 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
US10689416B2
(en)
*
|
2017-12-30 |
2020-06-23 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
CA3103920C
(en)
*
|
2018-06-22 |
2025-09-16 |
Ucl Business Ltd |
COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
|
|
US20240092831A1
(en)
*
|
2019-10-11 |
2024-03-21 |
Mayo Foundation For Medical Education And Research |
Proteasome Inhibitors
|
|
CN115038723A
(zh)
|
2019-11-18 |
2022-09-09 |
锡德克斯药物公司 |
烷基化环糊精组合物及其制备和使用方法
|
|
WO2021216670A1
(en)
*
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
US12698348B2
(en)
|
2020-09-24 |
2026-08-04 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
TW202430548A
(zh)
|
2022-09-29 |
2024-08-01 |
日商武田藥品工業股份有限公司 |
Ｃｄ３８結合融合蛋白組合療法
|
|
US20260166082A1
(en)
|
2022-11-02 |
2026-06-18 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
CN116768972A
(zh)
*
|
2023-06-25 |
2023-09-19 |
重庆药友制药有限责任公司 |
一种卡非佐米中间体的制备方法
|
|
AU2024321532A1
(en)
|
2023-08-09 |
2026-01-29 |
Amgen Inc. |
Diluted carfilzomib for use in treating multiple myeloma
|
|
EP4685151A1
(en)
|
2024-07-24 |
2026-01-28 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Proteasome inhibitor
|